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1. Introduction 
The characteristic elevation of plasma unesterified 
cholesterol and phospholipid concentrations in sub 
jects with biliary obstruction is due to the presence of 
an Abnormal low-density lipoprotein, LP-X, which 
does not react with antibodies to normal LDL [l-4]. 
The isolated lipoprotein, LP-X, is characterized by a 
low content of protein (5%) and a very high content 
of phospholipid (61-66%) and unesterified cholesterol 
(23-26%). Since several investigators [5-71 demon- 
strated immunochemically the presence of LP-A in 
the LDL fraction, it has been suggested [8,9] that the 
increased concentration of LDL in subjects with biliary 
obstruction is caused by a shift of a particular LP-A 
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Abbreviations of lipoproteins: VLDL, very low-density lipo- 
proteins, d < 1.006 g/ml; LDL, low-density lipoproteins, 
d 1.006-1.063 g/ml; HDL, high-density lipoproteins, d 1.063 
- 1.21 g/ml; q-LP, &lipoproteins characterized with an.electr@ 
phoretic mobility of Al-globulins; &LP, p-lipoproteins character- 
ized with an electrophoretic mobility of gglobulins; LP-A, 
lipoproteins characterized by the presence of apolipoprotein 
A (ApoA); LP-B, lipoproteins characterized by the presence 
of apolipoprotein B (ApoB); LP-C, lipoproteins characterized 
by the presence of apolipoprotein C (ApoC). Each apolipo- 
protein is characterized by its specific immunochemical 
characteristics and by such chemical properties as terminal 
amino acids. 
from the HDL into the LDL fraction. To study indi- 
vidual lipoproteins in the LDL fraction from subjects 
with biliary obstruction a procedure was developed in 
our laboratory [4] which makes possible the isolation 
of three immunochemically distinct lipoproteins, LP-A, 
LP-B and LP-X. The abnormal lipoprotein LP-X and 
the normal LP-B together accounted for 98%, and the 
LP-A for only 2%, of the total protein content of the 
LDL fraction. 
It has been demonstrated in our laboratory that 
human hyperlipemic plasma [10,l l] and normal post- 
prandial chyle VLDL [ 121 contain a protein moiety, 
apolipoprotein C, which differs immunochemically 
and chemically from the apolipoproteins A and B, 
the characteristic proteins of HDL and LDL, respec- 
tively. In this paper we are presenting evidence that the 
protein moiety of the abnormal low-density lipopro- 
teins in biliary obstruction consists of a combination 
of’albumin and apolipoprotein C. 
2. Materials and methods 
2.1. Isolation of LP-X 
Blood samples from four fasting patients with 
extra-hepatic biliary obstruction were collected into 
plastic bags containing 2.2% Na citrate and the plasma 
was recovered by low-speed centrifugation. LP-X was 
isolated by a previously-described procedure which 
combines heparin precipitation, ethanol fractionation 
and ultracentrifugation [4]. 
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2.2. Isolation of apolipoprotein C 
Blood was obtained from subjects with hypertri- 
glyceridemia (Types 3 or 5) 5 hr after ingestion of a 
heavy fat meal. Chyle was collected continuously 
over an 8 hr period following a fat meal by cannula- 
tion of the thoracic duct of a patient with normal 
fasting serum lipid levels (chyle was supplied by 
Dr. W.H.Falor, Akron City Hospital, Akron, Ohio). 
Plasma and chyle VLDL were isolated, purified and 
partially delipidized as previously described [ 11,121. 
The ApoA- and ApoB-containing phospholipid resi- 
dues were precipitated by adding successively to 
partially delipidized VLDL, solubilized in borate 
buffer, pH 9.0, equivalent amounts of rabbit anti- 
human sera LP-A (cuJ-LP) and LP-B (p-LP) (to avoid 
contamination with rabbit lipoproteins, the antisera, 
adjusted to d 1.25 g/ml, were centrifuged at 105,000 
X g for 44 hr and the floating lipoproteins were re- 
moved and discarded). The reaction mixtures were 
allowed to stand for 2 hr at 37” and the immuno- 
precipitates were sedimented by low-speed centrifu- 
gation (2,000 rpm) for 30 min. The density of the 
supernate remaining after the second immunoprecipi- 
tation was adjusted to 1.21 g/ml and the solution was 
centrifuged at 105,000 X g for 44 hr. The top fraction 
(upper 1 cm), removed by a tube-slicing technique, 
contained the ApoC-phospholipid residue and the 
bottom fraction consisted of a mixture of rabbit plas- 
ma proteins. ApoC (phosphorus content less than 0.1%) 
was obtained by five successive extractions of its 
protein-phospholipid residue with ethanol-diethyl 
ether (3: 1, v/v) at 0’. 
2.3. /mmunochemical methods 
The immunochemical properties of LP-X and ApoC 
were studied by double diffusion and/or immunoelec- 
trophoresis as previously described [4,11,12] _ Rabbit 
antihuman LP-A ((Y, -LP), LP-B @LLP), albumin and 
whole human serum were purchased from Behring- 
werke AG, Marburg-Lahn, Germany. Goat antirabbit 
whole serum and -y-globulin were obtained from Mann 
Research Laboratories, New York. Detailed procedures 
for the preparation and characterization of the purified 
rabbit antisera to LP-X [4] and VLDL [ 121 have been 
reported. The antibodies to LP-X reacted only with 
LP-X. The antisera to VLDL gave precipitin lines with 
partialIy delipidized VLDL; one of these precipitin 
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Fig. 1. Immunoelectrophoresis patterns of partially delipidized 
LP-X in 1% agar gel; partially delipidized LP-X before ultra- 
centrifugation, upper well, and, lower well, after removal of 
albumin by ultracentrifugation. Central trough contains anti- 
bodies to LP-X and albumin. 
lines gave an identity reaction with LP-A and the 
other with LP-B. The third precipitin line, character- 
istic of ApoC, showed no reaction with any available 
serum protein preparation. 
2.4. Electrophoresis 
The electrophoresis in 1% agar and 1% agarose 
gels was carried out as described under Immunochemi- 
cal methods. 
2.5. Chemical methods 
Determination of C-terminal amino acids with car- 
boxypeptidases A and B (Worthington Biochemical 
Corp. Freehold, New Jersey) was carried out according 
to the procedure by Ambler [ 131 . Lipid and protein 
analyses were performed according to methods pre- 
viously described [4, 1 l] . The anthrone-positive car- 
bohydrates were estimated by the method of Koehler 
r141. 
3. Results 
LP-X, characterized by a high phospholipid/protein 
ratio of 11.5 and single bands in agar and agarose elec- 
trophoresis, gave no reaction with antibodies to nor- 
mal whole serum, albumin, LP-A or LP-B; it reacted 
only with antibodies to LP-X [4]. However, LP-X 
partially delipidized by successive extractions with 
n-heptane according to the procedure by Gustafson 
[ 151 , gave a positive reaction not only with antibodies 
to LP-X, but also with antibodies to albumin (fig. 1, 
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Fig. 2. Immunodiffusion patterns of partially delipidized non-albumin protein of LP-X (central well in pattern a) and ApoC (cen- 
tral well in pattern b). Outer wells contain antibodies to LP-A (A), VLDL (B), LP-X (C), LP-B(D), whole serum (E) and albumin 
(F). Plate is stained with Amido Black 1 OB. 
upper portion). Separation of these two protein 
moieties was achieved by adjusting the density of 
partially delipidized lipoprotein solution to 1.21 g/ml 
and centrifuging the mixture at 105,000 X g for 
44 hr. The top fraction contained the non-albumin 
protein moiety reactive with antibodies to I..&X 
(fig. 1, lower portion) and the bottom fraction con- 
tained only the immunochemically identified albumin. 
Protein analysss of three separate partially delipidized 
LP-X samples showed that albumin accounted for 
approximately 40% and the ApoX for 60% of the 
total protein content. 
Partially and totally delipidized non-albumin pro- 
tein of LP-X moved as single fast bands in agar and 
agarose electrophoresis. Partially delipidized LP-X 
gave no reaction with antibodies to LP-A, LP-B, whole 
serum or albumin, but showed identical immuno- 
precipitin lines with antibodies to VLDL and LP-X 
(fig. 2, pattern a). Totally delipidized non-albumin 
protein, showing identical immunochemical behavior, 
contained traces of phospholipids (less than 0.1%) 
and no detectable free fatty acids or anthrone-positive 
carbohydrates. The C-terminal amino acid of the non- 
albumin protein was identified by the action of car- 
boxypeptidases A and B as alanine; kinetic studies 
indicated a C-terminal sequence: R-Val-Ala-Ala-COOH. 
The finding of a positive immunoprecipitin reac- 
tion of non-albumin protein with antibodies to VLDL, 
but not with antibodies to LP-A or LP-B, indicated 
similarity with ApoC. The mobility of partially and 
totally delipidized ApoC in agar and agarose elec- 
b 
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Fig. 3. Immunodiffusion patterns of partially delipidized non- 
albumin protein of LP-X (lower center well a) and ApoC 
(upper center well b). Outer wells contain antibodies to LP-X 
(A) and VLDL (B). Plate is stained with Amido Black 10B. 
trophoresis was the same as that of the non-albumin 
protein. Partially delipidized ApoC gave no reaction 
with antibodies to human LP-A, LPB, whole serum 
and albumin or with antibodies to rabbit whole 
serum or y-globulins, but showed total coalescence of 
precipitin lines with antibodies to VLDL and LP-X 
(fig. 2, pattern b). Its C-terminal amino acid and C- 
terminal sequence was the same as that of the non- 
albumin protein. A direct comparison of partially de- 
lipidized non-albumin protein and ApoC showed that 
these two proteins gave complete fusion of precipitin 
lines with antibodies to VLDL and LP-X (fig. 3). 
Totally delipidized non-albumin protein and ApoC 
gave identical immunochemical patterns. 
115 
Volume 4, number 2 FEBSLETTERS July 1969 
4. Discussion 
Results of the present study indicate that the ab- 
normal low-density lipoprotein in biliary obstruction 
contains a protein moiety of unique composition con- 
sisting of a combination of approximately 40% albu- 
min and 60% of a specific apolipoprotein. This ab- 
normal lipoprotein thus represents an albumin-lipo- 
protein complex in which the antigenic site of albu- 
min is revealed by partial or total delipidization. 
Since immunochemical studies have shown that the 
non-albumin protein and ApoC have a common anti- 
genie determinant, these two proteins are similar if 
not identical. This conclusion is further supported by 
the identical electrophoretic behavior on agar and 
agarose immunoelectrophoresis and C-terminal ana- 
lyses of both protein preparations. Although the 
questions about the molecular arrangement in the 
albumin-LP-X complex, the site of its formation, the 
reasons for its apparently exclusive occurrence in 
patients with obstructive jaundice [4] and the ad- 
ditional chemical evidence for the identity of the 
non-albumin protein and ApoC remain to be an- 
swered by further investigations, we are proposing 
as a working hypothesis that the formation and accu- 
mulation in serum of LP-X may be the result of an 
impaired catabolism of ApoC-containing lipoproteins 
caused by inhibitory action of increased concentra- 
tions of bile salts in the liver. 
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